This report was created for strategic planners, international marketing executives and export managers whose primary concern is the world market for glycosides, glands or other organs and extracts, antisera, vaccines, and similar products.
With the globalization of this market, managers can no longer be contented with a local view. Nor can managers be contented with out-of-date statistics that appear several years after the fact. I have developed a methodology, based on macroeconomic and trade models, to estimate the market for glycosides, glands or other organs and extracts, antisera, vaccines, and similar products for those firms serving the world via exports and foreign direct investment. It does so for the current year based on a variety of key historical indicators and econometric models.
In what follows, this report begins by summarizing the world exporter’s market for glycosides, glands or other organs and extracts, antisera, vaccines, and similar products. The total level of exports on a worldwide basis is based on a model that aggregates across over 150 key country markets and projects these to the current year.
From there, each country represents a percent of the world market. This market is served from a number of competitive countries of origin. Based on supply-side dynamics, market shares by country of origin are then calculated across each country market. These shares lead to a volume of import values for each country and are aggregated to regional and world totals. In doing so, we are able to obtain maximum likelihood estimates of both the value of each market and the shares that competitors (countries serving that market) are likely to receive this year.
From these figures, world rankings are calculated to allow managers to prioritize markets. In this way, all the figures provided in this report are forecasts that can be combined with internal information for strategic planning purposes.
Our reports have been used by over 10K customers, including:
This report was created for global strategic planners who cannot be content with traditional methods of segmenting world markets. With the advent of a "borderless world", cities become a more important criteria in prioritizing markets, as opposed to regions, continents, or countries. This report covers the top 2,000 cities in over 200 countries....
The global biologics safety testing market is projected to reach USD 6.2 billion by 2026 from USD 3.4 billion in 2021, at a CAGR of 12.4% during the forecast period. The growth of the global biologics safety testing market is driven by factors such as the growth in the biologics and biosimilars markets, growing concerns over cell culture contamination,...
529 pages •
By Global Industry Analysts
• Apr 2021
- Global Drug Discovery Technologies Market to Reach $74.3 Billion by 2027
- Amid the COVID-19 crisis, the global market for Drug Discovery Technologies estimated at US$44.2 Billion in the year 2020, is projected to reach a revised size of US$74.3 Billion by 2027, growing at aCAGR of 7.7% over the period...
Apoptosis Regulator BAX - Drugs In Development, 2021 Summary Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) - Apoptosis regulator BAX or bcl-2-like protein 4 is a protein is encoded by the BAX gene. It accelerates programmed cell death by antagonizing the apoptosis repressor BCL2....
120 pages •
By Infiniti Research Limited
• Jun 2021
Global Bioreactors Market 2021-2025 The analyst has been monitoring the bioreactors market and it is poised to grow by $ 3.99 billion during 2021-2025, progressing at a CAGR of 15.61% during the forecast period. Our report on the bioreactors market provides a holistic analysis, market size and forecast, trends, growth drivers,...
The Global Biologics CDMO Market was valued at USD 9.93 billion in 2020 and is expected to reach USD 18.63 billion by 2026, registering a CAGR of 10.87% during the forecast period (2021-2026). The CMO/CDMO service sector is uniquely positioned to address some of the challenges that drug developers are facing amid the COVID-19 pandemic....
175 pages •
By The Business Research Company
• Jun 2021
Major players in the vaccines market are AstraZeneca, Emergent Biosolutions, GlaxoSmithKline, Merck, and Pfizer Inc. The global vaccines market is expected to decline from $56.02 billion in 2020 to $55.97 billion in 2021 at a compound annual growth rate (CAGR) of -0.1%. The slow decline is mainly due to the outbreak of COVID-19 that...
The global oncology biosimilars market exhibited strong growth during 2015-2020. Cancer is a lifestyle disease that occurs due to the abnormal growth of cells and may result in the formation of a tumor. At present, most of the effective cancer treatments are based on biological drugs, also known as biologics, and include...
Biosimilar Penetration Rate
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.